Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (967)	10/1/1999 12:39:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 4974

I don't feel that there's much CTLA4-Ig in the price. Well they certainly talk about it enough. There are 2 major unpartnered programs (this and the autism stuff) - both pretty risky. Offsetting that is the steady income stream they get from Protein A, which isn't going to be enough to fund them. I agree it's less risky than say CTII or ARIA, but it's definitely a notch or two up from NPSP or NBIX. Peter

To: scaram(o)uche who wrote (967)	10/29/1999 4:29:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 4974

Rick, I just noticed in NPSP's 10Q that on September 27th they 'entered into a definitive agreement for a stock for stock merger with Allelix Biopharmaceuticals Inc. ("Allelix"), a Canadian company. NPS will be the surviving company and the combined company will operate as NPS Pharmaceuticals, Inc. in the U.S. and as NPS Allelix Inc. in Canada. . . . NPS will issue approximately 6.5 million shares of common stock to Allelix common shareholders at an exchange ratio of 0.3238 shares of NPS common stock for each outstanding share of Allelix stock. One million shares of NPS common stock will be reserved for issuance to the holders of Allelix options, warrants,and preferred stock at the same exchange ratio.' Its been a while since I subscribed to NeuroInvestment, but I remember that Harry Tracy used to speak very highly of Allelix. Sounds like a coup for NPSP. I haven't been a consistent follower of this thread, so apologies in advance if this is old news. Marc